Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK2 fusion |
| Therapy | Entrectinib |
| Indication/Tumor Type | biliary tract cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK2 fusion | biliary tract cancer | sensitive | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for biliary tract cancer patients harboring NTRK fusions who have progressed on or are intolerant of prior therapies (PMID: 39232586; ESMO.org). | 39232586 detail... |
| NTRK2 fusion | biliary tract cancer | sensitive | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring an NTRK fusion (PMID: 39864891; ESMO.org). | detail... 39864891 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| ESMO Clinical Practice Guidelines | Full reference... | |
| (39232586) | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. | Full reference... |
| (39864891) | ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. | Full reference... |